Leading preclinical brain imaging, with a main focus on PET imaging, and supporting brain imaging projects from collaborators.
Over the years, I have developed a strong interest for neuropathological conditions and their mechanisms, and how we could manipulate these molecular mechanisms to develop therapies. Understanding acute neuropathological conditions such as stroke or chronic brain diseases such as Alzheimer’s disease implies the ability to study in vivo the mechanisms of such conditions, hence my interest in animal models and in vivo imaging. I am particularly interested in the relation between inflammation, neuroinflammation and brain damage/neuronal loss.
To answer the numerous scientific questions involved in these processes, I have acquired a strong experience in several domains such as pharmacology of various neurotransmission systems (e.g. opioidergic, cholinergic, benzodiazepine), neuroscience, and neuroinflammation and neuropathological conditions such as Alzheimer’s disease or stroke. Over the years, I have acquired a good overview of the experimental approach of stroke, through model of brain ischaemia, and AD (transgenic mice and rats) and most importantly their respective strength and weaknesses (i.e. high reproducibility that translate poorly to clinical application, lack of comorbidities).
I had the opportunity to approach PET imaging during my PhD and I keenly grabbed the opportunity to return to PET imaging during my post-doc in Orsay before bringing that expertise back to Manchester. This technique obviously requires theoretical and practical knowledge of the biology it is applied to, but also knowledge in physiology and neuroanatomy, and basic knowledge in radiochemistry to liaise with the radiochemists efficiently. Computing and programming are almost compulsory in this field to enable efficient image analysis, data management and processing which fit quite well with my taste for programming.